# Schedules of Nab-Paclitaxel in Metastatic Breast Cancer

> **NCT01746225** · PHASE2 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 258 (actual)

## Conditions studied

- Metastatic Breastcancer

## Interventions

- **DRUG:** nab-Paclitaxel

## Key facts

- **NCT ID:** NCT01746225
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-05
- **Final completion:** 2023-03-16
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746225, "Schedules of Nab-Paclitaxel in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01746225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*